Bio-Rad Laboratories (NYSE:BIO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Bio-Rad Laboratories (NYSE:BIO - Free Report) from a hold rating to a buy rating in a research note published on Saturday.

A number of other research analysts have also recently commented on the stock. Wells Fargo & Company reduced their target price on shares of Bio-Rad Laboratories from $260.00 to $245.00 and set an "equal weight" rating on the stock in a research report on Monday, June 9th. Royal Bank Of Canada reduced their target price on shares of Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd. Citigroup reduced their target price on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Finally, UBS Group reduced their target price on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $324.25.

Bio-Rad Laboratories Trading Up 0.4%

BIO traded up $0.91 during trading on Friday, hitting $251.56. 109,086 shares of the company's stock were exchanged, compared to its average volume of 382,121. The stock has a 50 day moving average price of $235.85 and a 200 day moving average price of $271.75. Bio-Rad Laboratories has a 1 year low of $211.43 and a 1 year high of $387.99. The company has a current ratio of 5.99, a quick ratio of 4.43 and a debt-to-equity ratio of 0.18. The firm has a market cap of $6.84 billion, a P/E ratio of -3.30 and a beta of 0.95.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical research company reported $2.54 EPS for the quarter, topping analysts' consensus estimates of $1.73 by $0.81. Bio-Rad Laboratories had a negative net margin of 85.16% and a positive return on equity of 4.32%. The business had revenue of $585.40 million for the quarter, compared to analysts' expectations of $573.01 million. During the same period in the previous year, the company posted $2.30 earnings per share. The business's revenue for the quarter was down 4.2% compared to the same quarter last year. As a group, analysts expect that Bio-Rad Laboratories will post 10.81 EPS for the current fiscal year.

Institutional Trading of Bio-Rad Laboratories

Institutional investors have recently added to or reduced their stakes in the stock. Asset Management One Co. Ltd. raised its holdings in Bio-Rad Laboratories by 4.6% in the first quarter. Asset Management One Co. Ltd. now owns 7,182 shares of the medical research company's stock valued at $1,749,000 after acquiring an additional 315 shares in the last quarter. Blue Trust Inc. raised its holdings in Bio-Rad Laboratories by 35.2% in the first quarter. Blue Trust Inc. now owns 1,438 shares of the medical research company's stock valued at $350,000 after acquiring an additional 374 shares in the last quarter. LPL Financial LLC raised its holdings in Bio-Rad Laboratories by 34.3% in the fourth quarter. LPL Financial LLC now owns 5,195 shares of the medical research company's stock valued at $1,707,000 after acquiring an additional 1,326 shares in the last quarter. O Shaughnessy Asset Management LLC acquired a new stake in Bio-Rad Laboratories in the fourth quarter valued at $245,000. Finally, Two Sigma Investments LP raised its holdings in Bio-Rad Laboratories by 70.3% in the fourth quarter. Two Sigma Investments LP now owns 2,050 shares of the medical research company's stock valued at $673,000 after acquiring an additional 846 shares in the last quarter. 65.24% of the stock is owned by institutional investors and hedge funds.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.